» Articles » PMID: 33004756

Insufficient Radiofrequency Ablation Promotes Epithelial-mesenchymal Transition Mediated by Interleukin-6/signal Transducer and Activator of Transcription 3/Snail Pathway in the H22 Cells

Overview
Specialty Oncology
Date 2020 Oct 2
PMID 33004756
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Context: Radiofrequency ablation (RFA), an established and minimally invasive therapy for hepatocellular carcinoma, has become an important treatment strategy. However, tumor aggressiveness remains a common problem. The epithelial-mesenchymal transition (EMT) is thought to play an important role in this process.

Design And Aims: Due to limited sample volumes harvested from patients, we established a heat-treated cell line and a mouse model to investigate the mechanisms of incomplete ablation in EMT.

Materials And Methods: We heat-treated H22 and HepG2 cells using a water bath to determine a suitable temperature for incomplete RFA. Male BALB/c mice were orthotopically transplanted with H22 cells and then subjected to incomplete ablation. Changes in the EMT biomarkers were detected by real-time polymerase chain reaction, western blotting, and immunofluorescence.

Statistical Analysis: The experimental results are expressed as means ± standard deviations.

Results: Incomplete RFA promoted EMT, downregulated E-cadherin, upregulated vimentin and Snail, and enhanced the phosphorylation of signal transducer and activator of transcription 3 (STAT3) both in vivo and in vitro. Moreover, interleukin (IL)-6 secretion increased after heat treatment in the H22 cells. AG490, an IL-6 inhibitor, inhibited the occurrence of EMT.

Conclusions: Insufficient ablation performed at low temperature successfully induces EMT and promotes tumor aggressiveness, which is mediated by the IL-6/STAT3/Snail pathway in both cell and mouse models.

Citing Articles

Differential cytokine and chemokine expression after ablation vs. resection in colorectal cancer liver metastasis.

Frenkel N, Poghosyan S, van Wijnbergen J, Borel Rinkes I, Kranenburg O, Hagendoorn J Surg Open Sci. 2024; 18:29-34.

PMID: 38318321 PMC: 10838949. DOI: 10.1016/j.sopen.2024.01.005.


How Biology Guides the Combination of Locoregional Interventional Therapies and Immunotherapy for Hepatocellular Carcinoma: Cytokines and Their Roles.

Fu Y, Zeng C, An C, Liu Y, Shin J, Li X Cancers (Basel). 2023; 15(4).

PMID: 36831664 PMC: 9954096. DOI: 10.3390/cancers15041324.


Combinatory local ablation and immunotherapies for hepatocellular carcinoma: Rationale, efficacy, and perspective.

Chen S, Zeng X, Su T, Xiao H, Lin M, Peng Z Front Immunol. 2022; 13:1033000.

PMID: 36505437 PMC: 9726793. DOI: 10.3389/fimmu.2022.1033000.


Progression of hepatocellular carcinoma after radiofrequency ablation: Current status of research.

Wu S, Li Z, Yao C, Dong S, Gao J, Ke S Front Oncol. 2022; 12:1032746.

PMID: 36483051 PMC: 9723167. DOI: 10.3389/fonc.2022.1032746.


An Overview of Hepatocellular Carcinoma After Insufficient Radiofrequency Ablation.

Guo Y, Ren Y, Dong X, Kan X, Zheng C J Hepatocell Carcinoma. 2022; 9:343-355.

PMID: 35502292 PMC: 9056053. DOI: 10.2147/JHC.S358539.